Novartis Benefits From Lack of Generic Challenge

April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."
Will September Retest August Lows?
53:30 - Jacob Frenkel, chairman at JPMorgan Chase International, joins Bloomberg’s Vonnie Quinn to examine viewer responses to the Twitter question of the day. They speak on “Bloomberg Surveillance.” (Source: Bloomberg)
  • What's Holding Fed Back From Modest Rate Hike?
  • Securing Sustainable Economic Growth at All Costs
  • Will We See More Crises in Emerging Markets?